At CIRSE 2012 (Lisbon, Portugal, 15–19 September), Philips and Biocompatibles announced a collaboration to advance the use of image guidance to control the delivery of beads during the arterial embolization of hypervascularised tumours.
The first undertaking* of this new collaboration will be the development of a new treatment protocol for trans-arterial embolization―a process demonstrated to reduce the size or rate of growth of tumours. The aim of this protocol is to standardise and optimise the current approach to treatment delivery, thereby ensuring the best possible patient outcome.
The trend towards such minimally invasive treatments continues to grow in interventional oncology. This requires an integrated approach from image guidance and medical devices to provide controlled delivery of treatment that will both enable physicians to perform their procedures with more precision, and reduce discomfort for the patient.
“Personalised and less invasive treatment is the way forward in patient care,” said Louise Verheij, VP Marketing BU iXR. “As part of our strategy, Philips is committed to delivering integrated interventional solutions for image-guided minimally invasive procedures by working closely with hospitals and industry partners in different application spaces. Combining the leadership positions of Philips, in the field of advanced image guidance, and Biocompatibles, in the field of embolization beads, we strive to deliver reproducible and quantifiable results in image guided interventional oncology. This is an important step in helping advance patient care.”
“As a leader in beads for interventional oncology, we are investing in the optimisation techniques used for embolization procedures in order to further improve the safety and efficacy of the procedure at a macro level,” said Mike Motion, general manager Interventional Oncology, Biocompatibles. “Partnering with Philips will strengthen our ability to develop integrated techniques and image guidance to enhance the arterial embolization of hypervascularised tumours with beads, the ultimate objective being the advancement of interventional oncology.”
* Further to the planned protocol development, the scope of collaboration and development activities between Philips and BTG is currently being finalised, with additional announcements expected to be made in 2013.